Mirabegron

Mirabegron (YM-178) is a selective beta-3 adrenergic receptor (beta-3-AR) agonist approved in over 40 countries for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Developed by Astellas Pharma and first approved in Japan in 2011 and by the United States Food and Drug Administration in June 2012, mirabegron represented a paradigm shift in OAB pharmacotherapy as the first non-antimuscarinic agent approved for the indication, offering clinically meaningful efficacy with a substantially lower incidence of the dry mouth, constipation, and cognitive impairment that limit long-term adherence to antimuscarinic agents such as oxybutynin, tolterodine, solifenacin, darifenacin, and fesoterodine. The compound activates beta-3 adrenergic receptors on detrusor smooth muscle cells, producing cyclic adenosine monophosphate (cAMP)-mediated relaxation of the bladder wall during the storage phase and thereby increasing functional bladder capacity without impairing voiding contractility. At clinically approved doses (25 mg and 50 mg extended-release tablets administered once daily), mirabegron demonstrates high selectivity for the beta-3-AR over beta-1 and beta-2 adrenergic receptor subtypes, although modest beta-1-AR activity at supratherapeutic concentrations has been characterized and contributes to the dose-dependent cardiovascular signal (small increases in heart rate and blood pressure) that is the principal safety consideration in clinical use. The compound is also a moderate inhibitor of cytochrome P450 2D6 (CYP2D6), producing clinically relevant increases in systemic exposure to CYP2D6 substrates including metoprolol, desipramine, and thioridazine, a property that requires attention in polypharmacy contexts. Four pivotal Phase 3 randomized controlled trials (SCORPIO, ARIES, CAPRICORN, and DRAGON) enrolling over 4,500 patients established the efficacy and tolerability of mirabegron at 25 mg and 50 mg doses, demonstrating statistically significant reductions in mean daily micturition frequency and incontinence episodes compared to placebo over 12-week treatment periods, with efficacy sustained through 12-month extension studies. The safety profile in pooled clinical trial data and in extensive postmarketing surveillance confirms a low incidence of dry mouth (comparable to placebo), with the principal treatment-emergent adverse events being hypertension (7 to 11 percent), nasopharyngitis, urinary tract infection, and headache. Cardiovascular safety analyses, including a multinational non-interventional cohort study, have not identified increased risk of major adverse cardiovascular events relative to antimuscarinic comparators. Beyond the established OAB indication, mirabegron has attracted substantial research interest as a pharmacological activator of brown adipose tissue (BAT) thermogenesis through beta-3-AR-mediated stimulation of uncoupling protein 1 (UCP1) expression. Chronic mirabegron treatment in human subjects has been shown to increase BAT metabolic activity, resting energy expenditure, high-density lipoprotein cholesterol, adiponectin, and insulin sensitivity, positioning the compound as a research tool for metabolic disease and obesity pharmacology. Additional preclinical research has demonstrated antitumor activity through adipose tissue browning and modulation of the tumor microenvironment. This monograph reviews the chemistry, synthesis, and receptor pharmacology of mirabegron; the comprehensive human pharmacokinetic record including CYP2D6 inhibition; the clinical evidence base across OAB and emerging metabolic indications; the reconstitution, sourcing, and stack-interaction considerations for laboratory work; and a comparative assessment of five OAB pharmacotherapies against mirabegron on five competency standards.